$100+ Billion spent on myriad of acquisitions across Pharma and Biotech industries in H1 2018
Lloyd Price
JULY 5, 2018
As BioSpace noted when the deal was announced, Takeda will also take on a significant amount of debt through the deal, sending the price tag closer to $80 billion when that amount is included. Israel-based pharma giant Teva has also been in the midst of divesting itself of non-core assets as it looks to address debt of about $30 billion.
40 
Let's personalize your content